•  

Posts Tagged: Diabetes

Phase 2 clinical trial targeting diabetes

TIAP portfolio company Zucara Therapeutics moves their lead program targeting diabetes into Phase II clinical trials. Read more here. Why this news is important: Zucara has achieved the development milestones required to secure the remaining funds available from its previously announcedUS$21 million Series A Financing. Zucara plans to file an investigational new drug (“IND”) application for a Phase 2 trial by year end, with initiation of first patient dosing expected in Q1 2023. ZT-01 has the potential to become the first therapeutic designed ... Read more

Highly Positive Results from PoC Phase 1b trial of ZT-01 – Type 1 Diabetes

Zucara Therapeutics announced highly positive results from its proof-of-concept Phase 1b trial of ZT-01 in people with Type 1 diabetes (“T1D”). Please see the press release here. Why this news is important: This trial confirms ZT-01’s mechanism of action in restoring glucagon release in patients with T1D. First-in-class ZT-01, meaningfully restored glucagon release in nearly 90% of treated patients compared to placebo (p<0.0001). This therapy has the potential to become the first therapeutic to prevent hypoglycemia in people with insulin-dependent diabetes. Positive results from this trial will enable Zucara to further evaluate ZT-01 in a multi-center Phase 2 ... Read more

Funding for Zucara Therapeutics Expansion Into ZT-01 Development Program to Type 2 Diabetes

November 2, 2020: Zucara Therapeutics Inc., a diabetes life sciences startup funded by TIAP and adMare BioInnovations,  announced today that it has received funding from NRC IRAP and MITAS for its expansion into the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”). Red more here: https://bit.ly/34QRAn6 Read more

Zucara Therapeutics Announces US$21M Series A Financing

– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund  – TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The proceeds from the financing will fund Phase 1 and ... Read more

Zucara Therapeutics Secures Grant from GlycoNet

Toronto & Vancouver, Canada:  Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent diabetes, has secured a grant of $69,000 from Canadian Glycomics Network (GlycoNet) to expand and validate the model for its lead drug candidate “ZT-01” from type 1 diabetes (T1D) to type 2 diabetes (T2D). Zucara Therapeutics will match the funding with an additional $85,000 in cash and in-kind contributions, including scientific ... Read more

Important paper on Type 1 Diabetes and Exercise

New paper published in The Lancet Diabetes & Endocrinology recommends exercise guidelines for type 1 diabetes patients and healthcare providers. Experts from JDRF, the leading global organization focused on type 1 diabetes (T1D) research, as part of an international team of 21 researchers and clinicians led by York UniversityProfessor Michael Riddell, published first-of-its-kind guidelines to help people with type 1 diabetes exercise safely. The report, “Exercise management in type 1 diabetes: a consensus statement,” published this week in The Lancet Diabetes & Endocrinology, offers guidelines on ... Read more

Zucara Therapeutics Receives Cash Injection to Advance Novel Diabetes Drug Therapy to Prevent Hypoglycemia

VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI). This unique deal brings together three organizations mandated with enabling the growth of Canada’s health sciences sector. Each partner brings its respective strengths to the table: capital, ... Read more

Zucara Therapeutics inks license agreement with CDRD

This new license is an important step forward in bringing a new drug therapy closer to patients living with diabetes as it will enable us to access a promising lead drug candidate and position us to start clinical trials as early as 2018. Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has signed a licensing agreement with The Centre for Drug Research and Development (CDRD) for access to a ... Read more

Zucara Therapeutics Inc. developing drug to prevent hypoglycemic episodes for people with diabetes

TORONTO and VANCOUVER, CANADA (January 12, 2016) — A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being developed by Zucara Therapeutics Inc. This new start-up company, created by MaRS Innovation and The Centre for Drug Research and Development (CDRD) is based on decades of diabetes research by renowned University of Toronto (U of T) professor, Dr. Mladen Vranic. Zucara Therapeutics will attend Does of the Valley in February 2016. The ... Read more

MaRS Innovation forms third collaboration with Johnson & Johnson Innovation

MaRS Innovation today announced that Johnson & Johnson Innovation has expanded its collaboration with MaRS Innovation to identify and advance early-stage technologies of interest. The announcement was made in advance of the 2015 BIO Convention, which takes place from June 15 to 18 in Philadelphia, PA. MaRS Innovation is participating as part of the Ontario delegation and will have kiosk space in the Ontario pavilion (#615). This partnership was covered in BioCentury, GEN, PharmaBiz and FierceBiotech. Earlier this year, Johnson & Johnson Innovation and ... Read more
Page 1 of 212